论文部分内容阅读
目的观察新型腹腔引流器持续腹腔引流结合腹腔化疗治疗癌性腹水的疗效。方法将癌性腹水患者63例分为两组,治疗组32例,采用腹腔置入新型腹腔引流器,持续腹腔引流腹水并腹腔灌注化疗药物;对照组31例,采用传统的腹腔穿刺引流术放腹水。观察治疗组治疗前后患者尿量、腹围和体重变化,并比较两组疗效和不良反应。结果治疗组疗效优于对照组(p<0.05);与治疗前比较,治疗组治疗后尿量、腹围、体重有明显改变(p<0.05);生活质量提高、腹水平均控制时间,治疗组优于对照组(p<0.05);中位生存期、不良反应两组比较无明显差异(p>0.05)。结论新型腹腔引流器持续腹腔引流结合腹腔化疗治疗癌性腹水疗效好,不良反应少,患者依从性好。
Objective To observe the efficacy of a new type of peritoneal drainage device with continuous peritoneal drainage combined with intraperitoneal chemotherapy in the treatment of cancerous ascites. Methods Sixty-three patients with cancerous ascites were divided into two groups. The treatment group (32 cases) received intraperitoneal injection of a new type of peritoneal drainage device and sustained peritoneal drainage of ascites and intraperitoneal injection of chemotherapeutic drugs. The control group of 31 patients received conventional peritoneal drainage ascites. The changes of urine volume, abdominal circumference and weight before and after treatment in the treatment group were observed, and the curative effect and adverse reactions of the two groups were compared. Results Compared with the control group, the curative effect of the treatment group was better than that of the control group (p <0.05). After treatment, the urine output, abdominal circumference and body weight of the treatment group were significantly changed (p <0.05); the quality of life was improved; (P <0.05). There was no significant difference in median survival time and adverse reactions between the two groups (p> 0.05). Conclusion The new peritoneal drainage device with continuous intraperitoneal drainage combined with intraperitoneal chemotherapy for the treatment of cancerous ascites has good curative effect, less adverse reactions and good patient compliance.